The billionaire’s record has raised concerns over Neuralink’s ability to responsibly oversee the development of such an invasive device
Elon Musk’s brain-implant company Neuralink last week received regulatory approval to conduct the first clinical trial of its experimental device in humans. But the billionaire executive’s bombastic promotion of the technology, his leadership record at other companies and animal welfare concerns relating to Neuralink experiments have raised alarm.
“I was surprised,” said Laura Cabrera, a neuroethicist at Penn State’s Rock Ethics Institute about the decision by the US Food and Drug Administration to let the company go ahead with clinical trials.
About Author
More Stories
Sweden warns of heightened risk of Russian sabotage
NHS in England to trial AI tool to predict risk of fatal heart disease
Rise of almost untreatable superbug linked to a common antibiotic